Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATXI NASDAQ:BPTSY NASDAQ:INDP NASDAQ:LIPO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.77-7.9%$0.52$0.17▼$2.90$2.45M-0.07159,608 shs4,058 shsBPTSYBiophytis$2.00$1.84$1.33▼$5.97$702K0.861,668 shsN/AINDPIndaptus Therapeutics$2.41+5.5%$7.85$2.22▼$58.24$2.68M1.27113,904 shs314,153 shsLIPOLipella Pharmaceuticals$0.60-6.3%$0.66$0.55▼$7.31$2.77M-0.1799,983 shs2,001 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics+1.89%+14.14%+46.58%+221.97%-70.27%BPTSYBiophytis0.00%0.00%0.00%+44.93%-60.71%INDPIndaptus Therapeutics-11.63%-21.65%-70.29%-74.47%-94.61%LIPOLipella Pharmaceuticals-6.34%+2.16%-4.76%-77.78%-81.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.77-7.9%$0.52$0.17▼$2.90$2.45M-0.07159,608 shs4,058 shsBPTSYBiophytis$2.00$1.84$1.33▼$5.97$702K0.861,668 shsN/AINDPIndaptus Therapeutics$2.41+5.5%$7.85$2.22▼$58.24$2.68M1.27113,904 shs314,153 shsLIPOLipella Pharmaceuticals$0.60-6.3%$0.66$0.55▼$7.31$2.77M-0.1799,983 shs2,001 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics+1.89%+14.14%+46.58%+221.97%-70.27%BPTSYBiophytis0.00%0.00%0.00%+44.93%-60.71%INDPIndaptus Therapeutics-11.63%-21.65%-70.29%-74.47%-94.61%LIPOLipella Pharmaceuticals-6.34%+2.16%-4.76%-77.78%-81.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXIAvenue Therapeutics 0.00N/AN/AN/ABPTSYBiophytis 0.00N/AN/AN/AINDPIndaptus Therapeutics 3.00Buy$238.009,796.05% UpsideLIPOLipella Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXIAvenue TherapeuticsN/AN/AN/AN/A$1.92 per shareN/ABPTSYBiophytisN/AN/AN/AN/A($16.18) per shareN/AINDPIndaptus TherapeuticsN/AN/AN/AN/A$10.84 per shareN/ALIPOLipella Pharmaceuticals$536.36K5.17N/AN/A$1.59 per share0.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXIAvenue Therapeutics-$10.38M-$0.950.04∞N/AN/A-471.57%-296.50%11/12/2025 (Estimated)BPTSYBiophytis-$18.43MN/A0.00∞N/AN/AN/AN/AN/AINDPIndaptus Therapeutics-$15.02M-$37.66N/AN/AN/AN/A-612.59%-243.78%N/ALIPOLipella Pharmaceuticals-$5.02M-$3.43N/A∞N/A-988.83%-224.08%-172.88%N/ALatest BPTSY, ATXI, LIPO, and INDP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025INDPIndaptus Therapeutics-$0.36-$9.09-$8.73-$9.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATXIAvenue TherapeuticsN/AN/AN/AN/AN/ABPTSYBiophytisN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/AN/ALIPOLipella PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXIAvenue TherapeuticsN/A2.702.70BPTSYBiophytisN/A0.41N/AINDPIndaptus TherapeuticsN/A0.750.75LIPOLipella PharmaceuticalsN/A6.216.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXIAvenue Therapeutics17.34%BPTSYBiophytis0.05%INDPIndaptus Therapeutics7.06%LIPOLipella Pharmaceuticals74.31%Insider OwnershipCompanyInsider OwnershipATXIAvenue Therapeutics1.80%BPTSYBiophytis3.70%INDPIndaptus Therapeutics20.80%LIPOLipella Pharmaceuticals32.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATXIAvenue Therapeutics43.18 million2.02 millionNot OptionableBPTSYBiophytis30351,000338,000N/AINDPIndaptus Therapeutics61.11 million877,000Not OptionableLIPOLipella Pharmaceuticals44.62 million3.03 millionNot OptionableBPTSY, ATXI, LIPO, and INDP HeadlinesRecent News About These CompaniesLipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen PlanusSeptember 15 at 8:00 AM | prnewswire.comLIPO - Lipella Pharmaceuticals Inc Ordinary Shares Dividends | MorningstarJuly 18, 2025 | morningstar.comMLipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting - MorningstarJune 27, 2025 | morningstar.comMLipella Pharmaceuticals delisted from Nasdaq, explores relisting options amid ongoing operationsJune 27, 2025 | bizjournals.comLipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq DelistingJune 26, 2025 | finanznachrichten.deLipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq DelistingJune 25, 2025 | globenewswire.comNasdaq delists Lipella Pharmaceuticals over rule violationsJune 22, 2025 | investing.comLipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital MarketJune 21, 2025 | finanznachrichten.deLipella stock tumbles after Nasdaq delisting over rule violationsJune 20, 2025 | in.investing.comLipella Pharmaceuticals Announces Delisting from Nasdaq Capital MarketJune 20, 2025 | globenewswire.comLipella Pharmaceuticals Inc. Announces Issuance of U.S. Patent for Advanced Detection Method of Interstitial CystitisJune 17, 2025 | quiverquant.comQLipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic TechnologyJune 17, 2025 | globenewswire.comLipella Pharmaceuticals extends manufacturing pact with Cook MyoSiteJune 5, 2025 | investing.comLipella Re-Signs Manufacturing Collaboration Agreement with Cook MyoSiteJune 4, 2025 | contractpharma.comCLipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical DevelopmentJune 4, 2025 | prismmediawire.comPLipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical DevelopmentJune 4, 2025 | globenewswire.comLipella Pharmaceuticals to appeal Nasdaq noncompliance warningMay 20, 2025 | bizjournals.comLipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International MeetingMay 15, 2025 | prismmediawire.comPLipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International MeetingMay 15, 2025 | globenewswire.comLipella abstract on LP-10 for OLP accepted for presentation at AAOM, EAOMApril 25, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBPTSY, ATXI, LIPO, and INDP Company DescriptionsAvenue Therapeutics NASDAQ:ATXI$0.77 -0.07 (-7.85%) As of 02:26 PM EasternAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Biophytis NASDAQ:BPTSY$2.00 0.00 (0.00%) As of 09/12/2025Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.Indaptus Therapeutics NASDAQ:INDP$2.40 +0.13 (+5.48%) As of 03:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.Lipella Pharmaceuticals NASDAQ:LIPO$0.60 -0.04 (-6.34%) As of 01:16 PM EasternLipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Reddit Hits Record Highs: Why Wall Street Is Taking Notice Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
